Literature DB >> 27324856

The effect of ethyl pyruvate and N-acetylcysteine on ischemia-reperfusion injury in an experimental model of ischemic stroke.

Suha Turkmen1, Ozgen Cekic Gonenc2, Yunus Karaca2, Ahmet Mentese3, Selim Demir3, Ercument Beyhun4, Aynur Sahin2, Abdulkadir Gunduz2, Esin Yulug5, Suleyman Turedi2.   

Abstract

INTRODUCTION: Reperfusion therapies play an important role in early-period treatment for patients presenting to the emergency department due to stroke. However, the ischemia-reperfusion injury that may occur with reperfusion must then be considered. The purpose of this study was to determine the effectiveness of N-acetylcysteine (NAC) and ethyl pyruvate in preventing ischemia-reperfusion injury.
METHOD: This study is a randomized, controlled experimental study. In group 1, rats' left main carotid arteries were clamped. Reperfusion was established by releasing the clamp after 1.5 hours. In group 2, the left main carotid artery was clamped, and 20 mg/kg intraperitoneal NAC was administered after 1 hour. The clamp was released 0.5 hour after NAC administration. In group 3, rats' left carotid arteries were clamped, and 50 mg/kg ethyl pyruvate was administered intraperitoneally after 1 hour. The clamp was released 0.5 hour after ethyl pyruvate administration. All tissue samples were collected 2.5 hours after reperfusion. Brain tissues were compared histopathologically.
RESULTS: A higher percentage of degenerative neurons was determined in group 1 compared with groups 2 and 3 (P values: P(a) = .003 and P(c) = .003, respectively). A significant difference was also observed between groups 2 and 3 (P(b) = .003), with the percentage of degenerative neurons being lower in the NAC group than in the ethyl pyruvate group.
CONCLUSION: The use of NAC and ethyl pyruvate reduces injury resulting from ischemia-reperfusion in an experimental animal model of acute ischemic stroke and subsequent reperfusion.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27324856     DOI: 10.1016/j.ajem.2016.06.003

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  6 in total

Review 1.  Antioxidants in experimental ischemia-reperfusion injury of the testis: Where are we heading towards?

Authors:  George Vaos; Nick Zavras
Journal:  World J Methodol       Date:  2017-06-26

Review 2.  Deciphering the Iron Side of Stroke: Neurodegeneration at the Crossroads Between Iron Dyshomeostasis, Excitotoxicity, and Ferroptosis.

Authors:  Núria DeGregorio-Rocasolano; Octavi Martí-Sistac; Teresa Gasull
Journal:  Front Neurosci       Date:  2019-02-19       Impact factor: 4.677

Review 3.  The Potential for Natural Antioxidant Supplementation in the Early Stages of Neurodegenerative Disorders.

Authors:  Francesca Oppedisano; Jessica Maiuolo; Micaela Gliozzi; Vincenzo Musolino; Cristina Carresi; Saverio Nucera; Miriam Scicchitano; Federica Scarano; Francesca Bosco; Roberta Macrì; Stefano Ruga; Maria Caterina Zito; Ernesto Palma; Carolina Muscoli; Vincenzo Mollace
Journal:  Int J Mol Sci       Date:  2020-04-09       Impact factor: 5.923

4.  The neuroprotective effect of YaoYi-moxibustion on ischemic stroke by attenuating NK-κB expression in rats.

Authors:  Zheyi Zhou; Linglu Dun; Hong Xu; Peishan Yu; Cuilan Chen; Tao Si; Hongwei An; Junlei Lu; Bingxin Wei; Dongli Guo; Qian Yang; Na Zheng; Ping Yi
Journal:  Ann Transl Med       Date:  2022-07

5.  Ethyl pyruvate inhibits oxidation of LDL in vitro and attenuates oxLDL toxicity in EA.hy926 cells.

Authors:  Christine Rossmann; Christoph Nusshold; Margret Paar; Gerhard Ledinski; Erwin Tafeit; Martin Koestenberger; Eva Maria Bernhart; Wolfgang Sattler; Gerhard Cvirn; Seth Hallström
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

6.  Ethyl pyruvate improves white matter remodeling in rats after traumatic brain injury.

Authors:  Leilei Mao; Limin Sun; Jingyi Sun; Baoliang Sun; Yanqin Gao; Hong Shi
Journal:  CNS Neurosci Ther       Date:  2020-12-27       Impact factor: 7.035

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.